Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)

CompletedOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Degenerative Disc DiseaseBack Pain
Interventions
BIOLOGICAL

biologic, Osteocel Plus

Osteocel® Plus

Trial Locations (13)

14094

Buffalo Spine Surgery, Kenmore Mercy, Lockport

27710

Duke University Medical Center, Chapel Hill

30060

Pinnacle Orthopaedics, Wellstone Kennestone Hospital, Marietta

33021

Broward Spine Institute, Hollywood

33140

South Florida Spine Institute, Mount Sinai Medical Center, Miami Beach

33606

USF, Tampa General Hospital, Tampa

34232

Southeastern Spine Center, Doctors Hospital of Sarasota, Sarasota

46219

Indiana Center for Neurosurgery, Indianapolis

60540

The Spine Center of DuPage Medical Group, Edward Hospital, Naperville

65101

Spine Midwest, St. Mary's Health Center, Jefferson City

65205

Columbia Orthopaedic Group, Boone Hospital Center, Columbia

89109

Western Regional Center for Brain & Spine Surgery, Surgery Center of S. Nevada, Las Vegas

92037

Shiley Center for Orthopaedic, Scripps Green Hospital, La Jolla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NuVasive

INDUSTRY

NCT00948532 - Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®) | Biotech Hunter | Biotech Hunter